Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection

Derek J. Royer, Joshua F. Hendrix, Chelsea M. Larabee, Alaina M. Reagan, Virginie H. Sjoelund, Danielle M Robertson, Daniel J.J. Carr

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The cornea is essential for vision yet highly sensitive to immune-mediated damage following infection. Generating vaccines that provide sterile immunity against ocular surface pathogens without evoking vision loss is therefore clinically challenging. Here, we tested a prophylactic live-attenuated vaccine against herpes simplex virus type 1 (HSV-1), a widespread human pathogen that can cause corneal blindness. Parenteral vaccination of mice resulted in sterile immunity to subsequent HSV-1 challenge in the cornea and suppressed productive infection of the nervous system. This protection was unmatched by a relevant glycoprotein subunit vaccine. Efficacy of the live-attenuated vaccine involved a T-dependent humoral immune response and complement C3 but not Fcγ-receptor 3 or interferon-α/β signaling. Proteomic analysis of viral proteins recognized by antiserum revealed an unexpected repertoire dominated by sequestered antigens rather than surface-exposed envelope glycoproteins. Ocular HSV-1 challenge in naive and subunit-vaccinated mice triggered vision loss and severe ocular pathologies including corneal opacification, scar formation, neovascularization, and sensation loss. However, corneal pathology was absent in mice receiving the live-attenuated vaccine concomitant with complete preservation of visual acuity. Collectively, this is the first comprehensive report of a prophylactic vaccine candidate that elicits resistance to ocular HSV-1 infection while fully preserving the cornea and visual acuity.

Original languageEnglish (US)
Pages (from-to)827-839
Number of pages13
JournalMucosal Immunology
Volume12
Issue number3
DOIs
StatePublished - May 1 2019

Fingerprint

Herpetic Keratitis
Viral Antigens
Human Herpesvirus 1
Attenuated Vaccines
Vaccines
Cornea
Antibodies
Infection
Visual Acuity
Immunity
Glycoproteins
Pathology
Complement C3
Subunit Vaccines
Fc Receptors
Viral Proteins
Virus Diseases
Blindness
Surface Antigens
Humoral Immunity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection. / Royer, Derek J.; Hendrix, Joshua F.; Larabee, Chelsea M.; Reagan, Alaina M.; Sjoelund, Virginie H.; Robertson, Danielle M; Carr, Daniel J.J.

In: Mucosal Immunology, Vol. 12, No. 3, 01.05.2019, p. 827-839.

Research output: Contribution to journalArticle

Royer, Derek J. ; Hendrix, Joshua F. ; Larabee, Chelsea M. ; Reagan, Alaina M. ; Sjoelund, Virginie H. ; Robertson, Danielle M ; Carr, Daniel J.J. / Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection. In: Mucosal Immunology. 2019 ; Vol. 12, No. 3. pp. 827-839.
@article{57be3baa07e6431fba58f526e6f92353,
title = "Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection",
abstract = "The cornea is essential for vision yet highly sensitive to immune-mediated damage following infection. Generating vaccines that provide sterile immunity against ocular surface pathogens without evoking vision loss is therefore clinically challenging. Here, we tested a prophylactic live-attenuated vaccine against herpes simplex virus type 1 (HSV-1), a widespread human pathogen that can cause corneal blindness. Parenteral vaccination of mice resulted in sterile immunity to subsequent HSV-1 challenge in the cornea and suppressed productive infection of the nervous system. This protection was unmatched by a relevant glycoprotein subunit vaccine. Efficacy of the live-attenuated vaccine involved a T-dependent humoral immune response and complement C3 but not Fcγ-receptor 3 or interferon-α/β signaling. Proteomic analysis of viral proteins recognized by antiserum revealed an unexpected repertoire dominated by sequestered antigens rather than surface-exposed envelope glycoproteins. Ocular HSV-1 challenge in naive and subunit-vaccinated mice triggered vision loss and severe ocular pathologies including corneal opacification, scar formation, neovascularization, and sensation loss. However, corneal pathology was absent in mice receiving the live-attenuated vaccine concomitant with complete preservation of visual acuity. Collectively, this is the first comprehensive report of a prophylactic vaccine candidate that elicits resistance to ocular HSV-1 infection while fully preserving the cornea and visual acuity.",
author = "Royer, {Derek J.} and Hendrix, {Joshua F.} and Larabee, {Chelsea M.} and Reagan, {Alaina M.} and Sjoelund, {Virginie H.} and Robertson, {Danielle M} and Carr, {Daniel J.J.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1038/s41385-019-0131-y",
language = "English (US)",
volume = "12",
pages = "827--839",
journal = "Mucosal Immunology",
issn = "1933-0219",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection

AU - Royer, Derek J.

AU - Hendrix, Joshua F.

AU - Larabee, Chelsea M.

AU - Reagan, Alaina M.

AU - Sjoelund, Virginie H.

AU - Robertson, Danielle M

AU - Carr, Daniel J.J.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The cornea is essential for vision yet highly sensitive to immune-mediated damage following infection. Generating vaccines that provide sterile immunity against ocular surface pathogens without evoking vision loss is therefore clinically challenging. Here, we tested a prophylactic live-attenuated vaccine against herpes simplex virus type 1 (HSV-1), a widespread human pathogen that can cause corneal blindness. Parenteral vaccination of mice resulted in sterile immunity to subsequent HSV-1 challenge in the cornea and suppressed productive infection of the nervous system. This protection was unmatched by a relevant glycoprotein subunit vaccine. Efficacy of the live-attenuated vaccine involved a T-dependent humoral immune response and complement C3 but not Fcγ-receptor 3 or interferon-α/β signaling. Proteomic analysis of viral proteins recognized by antiserum revealed an unexpected repertoire dominated by sequestered antigens rather than surface-exposed envelope glycoproteins. Ocular HSV-1 challenge in naive and subunit-vaccinated mice triggered vision loss and severe ocular pathologies including corneal opacification, scar formation, neovascularization, and sensation loss. However, corneal pathology was absent in mice receiving the live-attenuated vaccine concomitant with complete preservation of visual acuity. Collectively, this is the first comprehensive report of a prophylactic vaccine candidate that elicits resistance to ocular HSV-1 infection while fully preserving the cornea and visual acuity.

AB - The cornea is essential for vision yet highly sensitive to immune-mediated damage following infection. Generating vaccines that provide sterile immunity against ocular surface pathogens without evoking vision loss is therefore clinically challenging. Here, we tested a prophylactic live-attenuated vaccine against herpes simplex virus type 1 (HSV-1), a widespread human pathogen that can cause corneal blindness. Parenteral vaccination of mice resulted in sterile immunity to subsequent HSV-1 challenge in the cornea and suppressed productive infection of the nervous system. This protection was unmatched by a relevant glycoprotein subunit vaccine. Efficacy of the live-attenuated vaccine involved a T-dependent humoral immune response and complement C3 but not Fcγ-receptor 3 or interferon-α/β signaling. Proteomic analysis of viral proteins recognized by antiserum revealed an unexpected repertoire dominated by sequestered antigens rather than surface-exposed envelope glycoproteins. Ocular HSV-1 challenge in naive and subunit-vaccinated mice triggered vision loss and severe ocular pathologies including corneal opacification, scar formation, neovascularization, and sensation loss. However, corneal pathology was absent in mice receiving the live-attenuated vaccine concomitant with complete preservation of visual acuity. Collectively, this is the first comprehensive report of a prophylactic vaccine candidate that elicits resistance to ocular HSV-1 infection while fully preserving the cornea and visual acuity.

UR - http://www.scopus.com/inward/record.url?scp=85060514474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060514474&partnerID=8YFLogxK

U2 - 10.1038/s41385-019-0131-y

DO - 10.1038/s41385-019-0131-y

M3 - Article

C2 - 30670763

AN - SCOPUS:85060514474

VL - 12

SP - 827

EP - 839

JO - Mucosal Immunology

JF - Mucosal Immunology

SN - 1933-0219

IS - 3

ER -